This Convalescent Plasma Therapy market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.
The convalescent plasma therapy market size has grown rapidly in recent years. It will grow from $0.05 billion in 2024 to $0.06 billion in 2025 at a compound annual growth rate (CAGR) of 11.4%. The growth in the historic period can be attributed to pandemics and infectious disease outbreaks, immunotherapy research, emergency use authorization (eua), patient availability, clinician and public awareness.
The convalescent plasma therapy market size is expected to see rapid growth in the next few years. It will grow to $0.09 billion in 2029 at a compound annual growth rate (CAGR) of 13.7%. The growth in the forecast period can be attributed to evolving pathogens, immunotherapies development, regulatory frameworks, global preparedness, public health initiatives. Major trends in the forecast period include standardized collection and processing, targeted plasma components, personalized treatment, telemedicine and remote monitoring, research into long-term effects.
Higher efficacy and safety demonstrated during trials for convalescent plasma therapy (CPT) in COVID-19 patients are expected to drive market growth in the forecast period. Convalescent plasma therapy has been a subject of interest during various infectious disease outbreaks, such as SARS‐1, Middle East Respiratory Syndrome (MERS), and 2009 H1N1. The results from studies, like the one conducted by Houston Methodist Hospital in June 2022, support its potential. The study indicated that convalescent plasma therapy was both safe (with no reported adverse events) and efficient, showing a 76% recovery rate for COVID-19 patients. In addition, a study published in the Journal of Medical Virology in May 2020 found that convalescent plasma therapy could potentially reduce mortality rates in critically ill patients, alleviate clinical symptoms, and lead to an increase in neutralizing antibody titers and the disappearance of SARS-CoV-2 RNA. As these studies confirm the safety and efficacy of CPT in treating COVID-19, the global convalescent plasma therapy market is poised for growth, driven by ongoing demand for treatments with proven benefits.
The increase in the number of hospitals is expected to propel the growth of the convalescent plasma therapy market. Hospitals are dedicated medical facilities providing a wide range of healthcare services, including diagnosis, treatment, and patient care. The rise in the number of hospitals often indicates improved healthcare infrastructure, offering better facilities for collecting, processing, and administering convalescent plasma. For instance, a report by Public Health Scotland in September 2022 indicated an increase in staffed beds for acute specialties, reaching an average of 13,323 in 2021/22, a 3.6% increase from the previous year (2020/21). Increased occupancy rates from 74.8% in 2020-21 to 84.2% in 2021/22 signify the growth in healthcare facilities. Therefore, the surge in hospital numbers is a key driver of the convalescent plasma therapy market.
The development of antibody-based immunotherapy for COVID-19 presents opportunities for the convalescent plasma therapy market. This therapy, which utilizes antibodies to enhance a patient's immunity, has garnered attention from companies investing in antibody-based COVID-19 treatments. For example, Regeneron Pharmaceuticals Inc. collaborated with the Biomedical Advanced Research and Development Authority (BARDA) to develop next-generation COVID-19 monoclonal antibody therapy. This focus on antibody-based COVID-19 therapy is likely to boost the convalescent plasma therapy market.
Major companies in the convalescent plasma therapy market are focusing on the development of innovative solutions, such as hyperimmune globulin therapies, to improve treatment efficacy and overcome the limitations of standard plasma therapies. Hyperimmune globulin therapies involve the use of plasma that is enriched with specific antibodies, typically collected from individuals who have recovered from a particular infection, offering potent and targeted immune support for patients. For example, in October 2023, Kamada Ltd., an Israel-based biopharmaceutical company, announced significant progress with its product CYTOGAM (Cytomegalovirus Immune Globulin Intravenous [Human]). After receiving FDA approval for its manufacturing facility in Israel, CYTOGAM became commercially available in the U.S. New clinical data presented at IDWeek 2023 revealed a five-year survival benefit for high-risk cytomegalovirus (CMV) mismatch lung transplant patients who received CYTOGAM. Additionally, Kamada formed its first Scientific Advisory Board to further enhance its U.S. clinical programs, positioning the company to make strides in the development of hyperimmune globulin therapies as a treatment for various infectious diseases. This move highlights the potential of hyperimmune globulin treatments to enhance convalescent plasma therapy and offer targeted, effective care for patients.
Major companies operating in the convalescent plasma therapy market include Bio Farma, Hilton Pharma Ltd., Biotest AG, BPL Ltd., LFB SA, Octapharma AG, CSL Behring LLC, Takeda Pharmaceutical Company Ltd., Orthosera Kft., ADMA Biologics Inc., GC Biopharma Corp, Grifols S.A, Sanquin Plasma Products B.V., America's Blood Centers, Blood Centers of America Inc., Anthem Inc., Laboratory Corporation of America Holdings, Cerus Corporation, Emergent BioSolutions Inc., Kedrion Biopharma Inc., New York Blood Center, Blood Systems Inc., OneBlood Inc., Gulf Coast Regional Blood Center, Bloodworks Northwest, Blood Assurance Inc., New York Blood Center Inc., Honolulu Blood-Plasma Bank, Community Blood Center, LifeStream Blood Bank.
Convalescent plasma refers to plasma obtained from individuals who have recuperated from an infection and contains antibodies targeting the specific microorganism responsible for the infection. It is employed in the treatment of patients afflicted by the same pathogen.
The principal antibody categories utilized in convalescent plasma therapy are Immunoglobulin M (IgM), Immunoglobulin G (IgG), and Immunoglobulin A (IgA). Immunoglobulin A (IgA) is a crucial antibody for immune activities within mucous membranes. Convalescent plasma finds various applications, including preventive measures (prophylaxis) and treatment, and is applied across a range of sectors, including hospitals, clinics, laboratories, and research institutes.
The convalescent plasma therapy market research report is one of a series of new reports that provides convalescent plasma therapy market statistics, including convalescent plasma therapy industry global market size, regional shares, competitors with a convalescent plasma therapy market share, detailed convalescent plasma therapy market segments, market trends and opportunities, and any further data you may need to thrive in the convalescent plasma therapy industry. This convalescent plasma therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
North America was the largest region in the convalescent plasma therapy market in 2024. Western Europe was the second largest region in the convalescent plasma therapy market. The regions covered in the convalescent plasma therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the convalescent plasma therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
The convalescent plasma therapy market includes revenue earned by IgD and IgE. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The convalescent plasma therapy market size has grown rapidly in recent years. It will grow from $0.05 billion in 2024 to $0.06 billion in 2025 at a compound annual growth rate (CAGR) of 11.4%. The growth in the historic period can be attributed to pandemics and infectious disease outbreaks, immunotherapy research, emergency use authorization (eua), patient availability, clinician and public awareness.
The convalescent plasma therapy market size is expected to see rapid growth in the next few years. It will grow to $0.09 billion in 2029 at a compound annual growth rate (CAGR) of 13.7%. The growth in the forecast period can be attributed to evolving pathogens, immunotherapies development, regulatory frameworks, global preparedness, public health initiatives. Major trends in the forecast period include standardized collection and processing, targeted plasma components, personalized treatment, telemedicine and remote monitoring, research into long-term effects.
Higher efficacy and safety demonstrated during trials for convalescent plasma therapy (CPT) in COVID-19 patients are expected to drive market growth in the forecast period. Convalescent plasma therapy has been a subject of interest during various infectious disease outbreaks, such as SARS‐1, Middle East Respiratory Syndrome (MERS), and 2009 H1N1. The results from studies, like the one conducted by Houston Methodist Hospital in June 2022, support its potential. The study indicated that convalescent plasma therapy was both safe (with no reported adverse events) and efficient, showing a 76% recovery rate for COVID-19 patients. In addition, a study published in the Journal of Medical Virology in May 2020 found that convalescent plasma therapy could potentially reduce mortality rates in critically ill patients, alleviate clinical symptoms, and lead to an increase in neutralizing antibody titers and the disappearance of SARS-CoV-2 RNA. As these studies confirm the safety and efficacy of CPT in treating COVID-19, the global convalescent plasma therapy market is poised for growth, driven by ongoing demand for treatments with proven benefits.
The increase in the number of hospitals is expected to propel the growth of the convalescent plasma therapy market. Hospitals are dedicated medical facilities providing a wide range of healthcare services, including diagnosis, treatment, and patient care. The rise in the number of hospitals often indicates improved healthcare infrastructure, offering better facilities for collecting, processing, and administering convalescent plasma. For instance, a report by Public Health Scotland in September 2022 indicated an increase in staffed beds for acute specialties, reaching an average of 13,323 in 2021/22, a 3.6% increase from the previous year (2020/21). Increased occupancy rates from 74.8% in 2020-21 to 84.2% in 2021/22 signify the growth in healthcare facilities. Therefore, the surge in hospital numbers is a key driver of the convalescent plasma therapy market.
The development of antibody-based immunotherapy for COVID-19 presents opportunities for the convalescent plasma therapy market. This therapy, which utilizes antibodies to enhance a patient's immunity, has garnered attention from companies investing in antibody-based COVID-19 treatments. For example, Regeneron Pharmaceuticals Inc. collaborated with the Biomedical Advanced Research and Development Authority (BARDA) to develop next-generation COVID-19 monoclonal antibody therapy. This focus on antibody-based COVID-19 therapy is likely to boost the convalescent plasma therapy market.
Major companies in the convalescent plasma therapy market are focusing on the development of innovative solutions, such as hyperimmune globulin therapies, to improve treatment efficacy and overcome the limitations of standard plasma therapies. Hyperimmune globulin therapies involve the use of plasma that is enriched with specific antibodies, typically collected from individuals who have recovered from a particular infection, offering potent and targeted immune support for patients. For example, in October 2023, Kamada Ltd., an Israel-based biopharmaceutical company, announced significant progress with its product CYTOGAM (Cytomegalovirus Immune Globulin Intravenous [Human]). After receiving FDA approval for its manufacturing facility in Israel, CYTOGAM became commercially available in the U.S. New clinical data presented at IDWeek 2023 revealed a five-year survival benefit for high-risk cytomegalovirus (CMV) mismatch lung transplant patients who received CYTOGAM. Additionally, Kamada formed its first Scientific Advisory Board to further enhance its U.S. clinical programs, positioning the company to make strides in the development of hyperimmune globulin therapies as a treatment for various infectious diseases. This move highlights the potential of hyperimmune globulin treatments to enhance convalescent plasma therapy and offer targeted, effective care for patients.
Major companies operating in the convalescent plasma therapy market include Bio Farma, Hilton Pharma Ltd., Biotest AG, BPL Ltd., LFB SA, Octapharma AG, CSL Behring LLC, Takeda Pharmaceutical Company Ltd., Orthosera Kft., ADMA Biologics Inc., GC Biopharma Corp, Grifols S.A, Sanquin Plasma Products B.V., America's Blood Centers, Blood Centers of America Inc., Anthem Inc., Laboratory Corporation of America Holdings, Cerus Corporation, Emergent BioSolutions Inc., Kedrion Biopharma Inc., New York Blood Center, Blood Systems Inc., OneBlood Inc., Gulf Coast Regional Blood Center, Bloodworks Northwest, Blood Assurance Inc., New York Blood Center Inc., Honolulu Blood-Plasma Bank, Community Blood Center, LifeStream Blood Bank.
Convalescent plasma refers to plasma obtained from individuals who have recuperated from an infection and contains antibodies targeting the specific microorganism responsible for the infection. It is employed in the treatment of patients afflicted by the same pathogen.
The principal antibody categories utilized in convalescent plasma therapy are Immunoglobulin M (IgM), Immunoglobulin G (IgG), and Immunoglobulin A (IgA). Immunoglobulin A (IgA) is a crucial antibody for immune activities within mucous membranes. Convalescent plasma finds various applications, including preventive measures (prophylaxis) and treatment, and is applied across a range of sectors, including hospitals, clinics, laboratories, and research institutes.
The convalescent plasma therapy market research report is one of a series of new reports that provides convalescent plasma therapy market statistics, including convalescent plasma therapy industry global market size, regional shares, competitors with a convalescent plasma therapy market share, detailed convalescent plasma therapy market segments, market trends and opportunities, and any further data you may need to thrive in the convalescent plasma therapy industry. This convalescent plasma therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
North America was the largest region in the convalescent plasma therapy market in 2024. Western Europe was the second largest region in the convalescent plasma therapy market. The regions covered in the convalescent plasma therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the convalescent plasma therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
The convalescent plasma therapy market includes revenue earned by IgD and IgE. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Convalescent Plasma Therapy Market Characteristics3. Convalescent Plasma Therapy Market Trends and Strategies4. Convalescent Plasma Therapy Market - Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market32. Global Convalescent Plasma Therapy Market Competitive Benchmarking and Dashboard33. Key Mergers and Acquisitions in the Convalescent Plasma Therapy Market34. Recent Developments in the Convalescent Plasma Therapy Market
5. Global Convalescent Plasma Therapy Growth Analysis and Strategic Analysis Framework
6. Convalescent Plasma Therapy Market Segmentation
7. Convalescent Plasma Therapy Market Regional and Country Analysis
8. Asia-Pacific Convalescent Plasma Therapy Market
9. China Convalescent Plasma Therapy Market
10. India Convalescent Plasma Therapy Market
11. Japan Convalescent Plasma Therapy Market
12. Australia Convalescent Plasma Therapy Market
13. Indonesia Convalescent Plasma Therapy Market
14. South Korea Convalescent Plasma Therapy Market
15. Western Europe Convalescent Plasma Therapy Market
16. UK Convalescent Plasma Therapy Market
17. Germany Convalescent Plasma Therapy Market
18. France Convalescent Plasma Therapy Market
19. Italy Convalescent Plasma Therapy Market
20. Spain Convalescent Plasma Therapy Market
21. Eastern Europe Convalescent Plasma Therapy Market
22. Russia Convalescent Plasma Therapy Market
23. North America Convalescent Plasma Therapy Market
24. USA Convalescent Plasma Therapy Market
25. Canada Convalescent Plasma Therapy Market
26. South America Convalescent Plasma Therapy Market
27. Brazil Convalescent Plasma Therapy Market
28. Middle East Convalescent Plasma Therapy Market
29. Africa Convalescent Plasma Therapy Market
30. Convalescent Plasma Therapy Market Competitive Landscape and Company Profiles
31. Convalescent Plasma Therapy Market Other Major and Innovative Companies
35. Convalescent Plasma Therapy Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Convalescent Plasma Therapy Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on convalescent plasma therapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for convalescent plasma therapy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The convalescent plasma therapy market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include: the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Antibody type: IgM; IgG; IgA2) By Application: Prophylaxis; Treatment
3) By End-Users: Hospitals and Clinics; Laboratories and Research institutes
Subsegments:
1) By IgM: Early-Stage Infection Plasma; Acute Phase Plasma; Other IgM-Based Plasma Products2) By IgG: High Titer IgG Plasma; Standard IgG Plasma; Other IgG-Based Plasma Products
3) By IgA: Plasma Rich in IgA; Specific IgA Antibody Plasma; Other IgA-Based Plasma Products
Key Companies Mentioned: Bio Farma; Hilton Pharma Ltd.; Biotest AG; BPL Ltd.; LFB SA
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
The major companies featured in this Convalescent Plasma Therapy market report include:- Bio Farma
- Hilton Pharma Ltd.
- Biotest AG
- BPL Ltd.
- LFB SA
- Octapharma AG
- CSL Behring LLC
- Takeda Pharmaceutical Company Ltd.
- Orthosera Kft.
- ADMA Biologics Inc.
- GC Biopharma Corp
- Grifols S.A
- Sanquin Plasma Products B.V.
- America's Blood Centers
- Blood Centers of America Inc.
- Anthem Inc.
- Laboratory Corporation of America Holdings
- Cerus Corporation
- Emergent BioSolutions Inc.
- Kedrion Biopharma Inc.
- New York Blood Center
- Blood Systems Inc.
- OneBlood Inc.
- Gulf Coast Regional Blood Center
- Bloodworks Northwest
- Blood Assurance Inc.
- New York Blood Center Inc.
- Honolulu Blood-Plasma Bank
- Community Blood Center
- LifeStream Blood Bank
